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Hemolytic uremic syndrome (HUS) is characterized by thrombotic microangiopathy of the
glomerular microcirculation and other vascular beds. Its defining clinical phenotype is acute
kidney injury (AKI), microangiopathic anemia, and thrombocytopenia. There are many eti-
ologies of HUS including infection by Shiga toxin-producing bacterial strains, medications,
viral infections, malignancy, and mutations of genes coding for proteins involved in the
alternative pathway of complement. In the aggregate, although HUS is a rare disease, it is
one of the most common causes of AKI in previously healthy children and accounts for a
sizable number of pediatric and adult patients who progress to end stage kidney disease.
There has been great progress over the past 20 years in understanding the pathophysiology
of HUS and its related disorders. There has been intense focus on vascular injury in HUS
as the major mechanism of disease and target for effective therapies for this acute illness.
In all forms of HUS, there is evidence of both systemic and intra-glomerular inflammation
and perturbations in the immune system. Renewed investigation into these aspects of
HUS may prove helpful in developing new interventions that can attenuate glomerular and
tubular injury and improve clinical outcomes in patients with HUS.
Keywords: thrombotic microangiopathy, hemolytic uremic syndrome, Shiga toxin, inflammation, alternative
pathway of complement
INTRODUCTION
Hemolytic uremic syndrome (HUS) is characterized by general-
ized thrombotic microangiopathy (TMA) and the clinical triad of
acute kidney injury (AKI), microangiopathic anemia, and throm-
bocytopenia (1). HUS is classified into three categories: (i) typical
disease that occurs sporadically or in epidemic outbreaks and
that is related to antecedent infection with Stx-producing strains
of E. coli (STEC) or other microorganisms that elaborate Shiga
toxin (Stx); (ii) sporadic atypical cases that occur secondary to
infections, medication use, systemic disease, or malignancy; and
(iii) familial atypical cases that are predominantly due to genetic
abnormalities in complement regulatory proteins (1, 2) (Table 1).
Hemolytic uremic syndrome is a perennial topic for review
articles. Therefore, in an attempt to provide new insight into the
disease, in this mini-review we will highlight the role of inflam-
mation in both typical and atypical forms of HUS. Our intent is to
indicate the potential of anti-inflammatory therapies to improve
outcomes in patients with all forms of this disease.
EPIDEMIOLOGY
All forms of HUS, taken collectively, qualify for the official rare
disease designation, i.e., <200,000 cases per year in the US. The
incidence of STEC–HUS has been steady and ranges from 6 per
100,000 in children under the age of 5 years to 1–2 per 100,000 in
the overall population (1, 2) (Table 1). STEC–HUS disease affects
girls more than boys, and occurs in all racial and ethnic groups
except African Americans who are less likely to be affected (3).
In epidemics, STEC–HUS may occur in a wider age spectrum.
During the 2011 outbreak centered in Germany, 3,816 patients,
predominantly adults, were infected by E. coli strain O104:H4,
among whom there were 845 HUS cases, and 54 deaths (4).
The incidence of both non-familial aHUS and familial aHUS
is lower than STEC–HUS. Together, they occur at a rate that is at
most 10% of that for STEC–HUS and it is estimated that their
total incidence is approximately 2–5 cases/million population per
year (5). There is no increased susceptibility by gender or racial
group for these two subcategories of HUS.
CLINICAL FEATURES OF HUS
The presentation of HUS is usually abrupt and the diagnosis is
made promptly. Patients develop pallor and noticeable oliguria
within 1–2 days of the onset of the disease. STEC–HUS occurs
approximately 6–14 days after ingestion of contaminated food or
beverage and 2–6 days after the onset of enteritis. Diarrhea occurs
in over 90% of cases of STEC enteritis. It is accompanied by severe
crampy abdominal pain and stools that change from watery to
hemorrhagic.
Non-familial forms of aHUS occur sporadically. Children with
pneumococcal HUS tend to be young with a mean age of 1–2 years
and have more severe disease compared to STEC–HUS. Up to
80% of affected patients require acute dialysis, compared to 40%
in STEC–HUS; however, most children recover and have normal
kidney function at long-term follow-up (5).
Patients with familial aHUS can present in childhood or adult-
hood (6, 7). They develop the disease throughout the year and at
variable intervals after the triggering event. aHUS can be preceded
by an episode of gastroenteritis, which can create uncertainty
about the diagnosis.
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Table 1 | Clinical taxonomy of HUS.
STEC–HUS Atypical HUS
non-familial
Atypical HUS
familial
Cause Shiga toxin
producing
bacteria
Infections
Medications
Malignancy
Genetic defects in
regulation of alternative
complement cascade
Incidence 1–3/105
population
Unknown 1–3/106 population
Need for RRT 40% 30% 50–60%
Mortality 3–5% Depends on
underlying
disease
25%
Recurrence Rare Rare 25–50%
Progression to
ESKD
<10% Depends on
underlying
disease
50–70%
Patients with HUS invariably have hypertension, hyperkalemia,
and other electrolyte abnormalities such as hyponatremia and
hypocalcemia as a consequence of the kidney injury. Nearly 40% of
patients with STEC–HUS and up to 70% of cases of aHUS require
renal replacement therapy during the acute episode (3, 6).
CLINICAL CAUSES/ETIOLOGY
Stx-PRODUCING STRAINS OF E. COLI -HEMOLYTIC UREMIC SYNDROME
E. coli O157:H7 remains the most common strain that causes
STEC–HUS (3). However, non-O157 E. coli serotypes are an
increasingly prevalent cause of STEC–HUS. Between 2000 and
2006, these strains accounted for half of all STEC infections and
the same percentage of isolates produced Stx2 as O157 strains (8).
NON-FAMILIAL aHUS
The most common infectious trigger is S. pneumonia, linked to
neuraminidase production by the microorganism (5). The inci-
dence has been steady because pneumococcal-related HUS is
caused by bacterial strains, such as serotype 19A, that are not
included in 7- or 23-valent pneumococcal vaccines (9). Other
infectious causes include HIV, Mycoplasma pneumoniae, Histo-
plasmosis, and Coxsackie virus. It is important to note that STEC
can also be associated with sporadic cases of HUS that resemble
non-familial aHUS. Pharmacologic causes of aHUS include cal-
cineurin inhibitors; antiplatelet drugs; chemotherapeutic agents,
such as cisplatinum and gemcitabine; and biologics, such as the
VEGF inhibitor, bevacizumab (10). SLE, the anti-phospholipid
syndrome, and pregnancy can also lead to aHUS.
FAMILIAL aHUS
Forty-four to sixty-six percent of patients with familial aHUS have
one or more mutations in a complement regulatory protein (11).
Combined mutations occur in <10% of cases and are more com-
mon in those with MCP or factor I mutations (12). The genetic
defects in patients with aHUS generally demonstrate incomplete
penetrance, indicating that additional factors are needed for the
disease to be manifest. The presence of combined mutations or
single mutations along with specific risk haplotypes is most sig-
nificant for patients with MCP mutations because that subgroup
had an increased risk of progression to ESKD and less favorable
outcomes after kidney transplant (13). The gene that has been
most recently linked to aHUS is diacylglycerol kinase ε (DGKE),
an enzyme present in endothelial cells. The altered DGKE protein
activated protein kinase C and caused a prothrombotic state (14).
The impact of this protein on the alternative pathway of com-
plement (APC) is unresolved because hypocomplementemia has
been documented in a patient with a DGKE mutation (15).
PATHOPHYSIOLOGY
VASCULAR INJURY
In HUS, the primary site of damage is the vascular endothelial
cell with secondary injury occurring in the tubular epithelial cell
and the podocyte. The endothelium becomes detached from the
underlying basement membrane and the subendothelial space
is filled with amorphous material and fibrin. Within the vascu-
lar lumen, there are platelet-fibrin thrombi that can completely
occlude the vessel (16).
Stx-producing strains of E. coli-hemolytic uremic syndrome
When a person becomes infected with an STEC, bacteremia does
not ensue. Instead, Stx crosses the gastrointestinal epithelium
via a transcellular pathway, and enters the bloodstream (17). Stx
binds to neutrophils, which convey it to the peripheral vascu-
lature (18). Neutrophil-associated Stx is detectable in 60% of
patients and the amount correlates with the extent of kidney
injury (19).
In vascular beds, Stx binds to the glycosphingolipid, globo-
triaosylceramide (Gb3) on glomerular endothelial cells, mesangial
cells, podocytes, and tubular epithelial cells (1, 2). The glomerular
microcirculation is a key target of Stx because of high renal blood
flow and enhanced expression of Gb3 but Stx also binds to the
endothelium in other organs, especially the brain (20). After bind-
ing, Stx is internalized and transported to the Golgi apparatus and
then in a retrograde pathway to the endoplasmic reticulum where it
inhibits protein synthesis leading to cell death and apoptosis (21).
The intracellular trafficking of Stx is blocked by manganese and
administration of this cation protects against Stx-induced disease
in experimental animals (22).
The vascular damage triggered by Stx promotes release of
thrombin and increased fibrin concentrations. High levels of
plasminogen activator inhibitor-1 (PAI-1) block fibrinolysis and
accelerate thrombosis (23). Increased shear stress within occluded
vessels perturbs processing of VWF multimers with uncoiling
of the molecule. These alterations activate platelets and aug-
ment thrombus formation (23, 24). Angiopoietins are mole-
cules that regulate angiogenesis by interacting with the Tie-2
receptor on the endothelial cell surface. Because of the piv-
otal role of endothelial injury in STEC–HUS, their role has
been studied in this condition. Thus, children with STEC–HUS
have reduced levels of angiopoietin-1 (anti-inflammatory) and
increased levels of angiopoietin-2 (inflammatory) during the
prodromal phase that worsen with progression of the microan-
giopathy. These alterations in endothelial function may potentiate
systemic inflammation (25).
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aHUS
In non-familial aHUS, injury to endothelial cells is directly caused
by the offending agent. In familial aHUS, even slight endothelial
damage during a mild viral respiratory illness can trigger TMA
because of defective regulation of the APC (26). The alternative
complement cascade is constitutively active because binding of
C3 to factor B generates a catalytically active complex that leads
to continued formation of C3bBb, the alternative pathway conver-
tase. A number of circulating (Factors B, H, and I) and membrane-
bound (MCP, thrombomodulin) molecules interact to prevent
continuous activation of the pathway and endothelial injury (27).
Both inactivating (Factor H and I) and activating mutations (Fac-
tor B and C3) enhance complement cascade activity and promote
development of aHUS (6). Newly discovered mutations, including
DGKE, have been associated with aHUS, but the contribution of
APC activation in these cases is unresolved (14, 15).
INFLAMMATION
It has been evident from the time that HUS was recognized as a
distinct clinical entity that inflammation plays a key role in the
pathogenesis of the illness. However, it is important to recog-
nize that the contribution of specific mediators is often limited
by the small size of the patient cohorts, lack of serial sampling,
and inability to test the impact of antagonists or inhibitors of
the molecule of interest. Most of the literature on the inflam-
mation in HUS is over a decade old, suggesting that this aspect
of the disease has been largely neglected for the last 10 years.
In the following paragraphs, the role of discrete components
of the inflammatory response in the subcategories of HUS is
summarized, primarily STEC-related disease. We highlight those
studies that provide the strongest support for this pathogenetic
pathway.
Stx-producing strains of E. coli-hemolytic uremic syndrome is
associated with many inflammatory changes (Table 2) that may act
as targets for new interventions. In a review of published literature,
we were unable to identify studies that assessed these inflamma-
tory processes in patients with aHUS. The exception is changes in
complement, which have been explored in both types of HUS (7)
(see below).
Polymorphonuclear cells and monocytes
The addition of Stx2 to human bone marrow or cord blood cells
in culture induces macrophage–granulocyte colonies (28). Poly-
morphonuclear (PMN) from Stx2-treated mice reveal increased
expression of CD11b, greater adhesive properties, and enhanced
cytotoxic capacity (29). Neutrophils contribute directly to renal
inflammation and endothelial injury in HUS through the delivery
of Stx to the glomerular microcirculation (18). PMN depletion
reduces Stx2-induced cytotoxicity and renal damage (30).
In patients, who develop STEC–HUS, there is a 10-fold higher
level of granulocyte stimulating factor, leukocytosis, and increases
in absolute PMN and monocyte counts (31, 32). Based on biopsies
done during the early phase of the disease, infiltration of the kid-
ney by PMN is common in patients with STEC–HUS and atypical
forms of the disease (24). Despite eventual PMN clearance from
the kidneys after 2–3 weeks, a high peripheral blood PMN count
at diagnosis is associated with a poor prognosis.
Table 2 | Inflammatory mediators in HUS.
STEC–HUS Atypical HUS Targeted therapies
Leukocytes +++ + None
Chemokines IL-8 No data None
MCP-1
CXCR1
CXCR4/7-SDF-1
Cytokines IL-6 No data ?Anti-TNF-α agents
TNF-α ?Anti-IL-6 agents
p38 inhibitors
Complement + ++++ Eculizumab
?, Uncertain clinical value.
Chemokines
Strains of E. coli-hemolytic uremic syndrome is marked by the
induction of various chemokines that recruit leukocytes to the kid-
neys. Mice exposed to Stx2 and lipopolysaccharide (LPS) showed
higher levels of monocyte chemoattractant peptide-1 (MCP-1),
macrophage inflammatory protein-1α (MIP-1α), and regulated
on activation normal T cell expressed (RANTES), and increased
macrophage recruitment to the kidney, compared to controls.
Mice that were treated with neutralizing antibodies to these
chemokines had decreased renal fibrin deposition (33).
Mice with Stx-induced HUS and knockout of chemokine (C-
C motif) receptor 1 (CCR1) have improved survival, attenuated
neutrophilia and monocytosis, reduced renal damage, and less-
ened PMN and monocyte renal infiltration compared to wild type
animals. The rise in plasma tumor necrosis factor-α (TNF-α) and
IL-6 levels was delayed in CCR1 knockout mice (34). The plasma
concentration of these chemokines is acutely elevated in patients
with STEC–HUS (35).
Stromal derived factor-1 is a potent chemoattractant cytokine
that modulates stem cell mobilization, inflammatory cell infiltra-
tion, and angiogenesis via interaction with its receptor chemokine
(C-X-C motif) receptor 4 (CXCR4). Treatment of human
microvascular endothelial cells with Stx2 induced the expres-
sion of CXCR4, CXCR7, and stromal derived factor-1 (SDF-1).
In a murine model of HUS, inhibition of the CXCR4/SDF-1
interaction decreased endothelial activation and kidney injury,
and improved animal survival. Children infected with E. coli
O157:H7 who progress to HUS have higher plasma concentrations
of SDF-1, the endogenous ligand for CXCR4/CXCR7 chemokine
receptor, compared to children whose enteritis resolves without
complications (36).
Cytokines
Patients with STEC–HUS have higher plasma levels of TNF-α,
IL-6, and lower levels of IL-10 compared to normal controls, a
process driven in part by increased expression of Toll-like receptor
on circulating PMN (37, 38). Isolated monocytes from children
with STEC–HUS that are incubated with Stx1 produce IL-1β, IL-
6, IL-8, and TNF-α (39). Preincubation of human endothelial cells
with TNF-α or IL-1 results in an increase in Gb3 synthesis and
increased Stx1 binding (40).
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Circulating levels of TNF-α and IL-6 correlate with the severity
of STEC–HUS and the occurrence of extra-renal complications.
Similarly, monocyte production of TNF-α and IL-10 increases in
parallel with the intensity of disease in children with STEC–HUS.
Patients with moderate-to-severe disease had the greatest number
of TNF-α producing monocytes (38). Patients who progressed to
severe renal dysfunction had a 10-fold increase in IL-6 compared
to those who maintained diuresis (41). Elevated concentrations of
select cytokines, IL-6, and soluble TNF receptor 1, were associated
with the occurrence of encephalopathy (42).
Complement
In a subset of patients with STEC–HUS, low levels of C3 have
been documented in conjunction with increased levels of comple-
ment degradation products (C3b, C3c, and C3d) and deposition of
complement components in kidney tissue (43, 44). A retrospective
analysis of 17 patients with STEC–HUS found evidence of APC
activation, based on high levels of factor Bb and soluble C5b-9 in
the plasma, in all cases (3, 45). There is complement activation on
platelet–leukocyte complexes and platelet- and monocyte-derived
microparticles in the circulation of children with STEC–HUS (46).
In vitro incubation of microvascular endothelial cells with Stx and
murine models of STEC–HUS causes increased expression of P-
selectin and activation of C3 via the complement cascade (47). Stx
induces podocyte injury in mice via the activation of the APC and
generation of C3a (48).
Patients with aHUS have reduced serum complement levels
at diagnosis. In a study of 15 cases, decreased serum C3 level
was noted in 73% of affected patients. A low C3 was associated
with relative risk of developing HUS of 16.6 within families and
of 27.8 in the overall population (12). Nearly 50% of cases of
familial aHUS are due to activating mutations in proteins in the
APC (e.g., C3, Factor B) or inactivating mutations in proteins
that prevent overactivation of this cascade (16). It is worth not-
ing that the same genetic abnormalities that cause aHUS have
been linked to the development of C3 glomerulopathy and mem-
branoproliferative glomerulonephritis, indicating that they can
also lead to glomerular inflammation (49). The role of comple-
ment in aHUS has been the subject of intensive investigation
and the reader is referred to an excellent up-to-date review by
Noris et al. (7).
TREATMENT
Stx-PRODUCING STRAINS OF E. COLI -HEMOLYTIC UREMIC SYNDROME
Provision of adequate amounts of sodium-containing intravenous
fluids during the prodromal phase may prevent activation of
the coagulation cascade within the glomerular microcirculation
and prevent progression of STEC enteritis to HUS (50). There
is no proven therapy for STEC–HUS that reduces the need for
acute renal replacement therapy, shortens the course, or improves
long-term outcomes. Therefore, treatment centers on supportive
management of AKI, anemia, hypertension, and fluid-electrolyte
imbalances. Renal replacement therapy is advised if there is anuria
for at least 24 h or oliguria (<0.5 ml/kg/h) for at least 72 h (51)
(Table 3).
The agent that has received the most attention recently as a
potential treatment for STEC–HUS is eculizumab, a monoclonal
Table 3 | Overall approach to the treatment of children with HUS.
STEC–HUS Non-familial
aHUS
Familial
aHUS
Intensive
supportive care
+ + +
Treat triggering
illness
− + −
Antibiotics of no
value
Eculizumab ? − ++
Plasmapheresis − ? +
No supportive
data
Temporarily until
start of eculizumab
treatment
?, Uncertain clinical value.
antibody to C5a. In the midst of the large German outbreak
of STEC–HUS due to O104:H4 in 2011, a Letter to the Editor
of the New England Journal of Medicine described three chil-
dren, all 3 years of age, with severe STEC–HUS that required
dialysis, who were treated with eculizumab (52). Their neuro-
logical status, platelet count, and LDH improved dramatically
after the first dose. Dialysis was discontinued within 16 days and
all three children were discharged without neurological find-
ings. German nephrologists received emergency authorization to
administer the antibody for “off-label” compassionate use dur-
ing the outbreak and a total of 328 patients with STEC–HUS
received eculizumab (53). Furthermore, open label treatment of
nine patients in France during the outbreak promoted more
rapid recovery of renal and neurological function (54). In con-
trast, in a report describing 90 children during the outbreak, of
whom 13 received eculizumab (together with plasma exchange
in 7 cases), the vast majority recovered and only 1 child died.
The authors concluded that O104:H4 STEC–HUS is compara-
ble to the O157 serotype and that there is no need for novel
treatments such as eculizumab (55). A randomized clinical trial
is needed to define the place of eculizumab in the management of
STEC–HUS.
ATYPICAL HUS
Administration of the eculizumab to 37 patients with aHUS and
renal damage (17 with plasma-resistant and 20 with plasma-
responsive disease) resulted in a significant increase in platelet
count and achievement of a TMA-event free status in 80% of cases
(56). Following FDA approval in September 2011, eculizumab
has become the standard of care for all patients with aHUS.
Discontinuation of eculizumab has been associated with recur-
rence of disease (unpublished observations) and Alexion (the
manufacturer) recommends maintaining antibody therapy indef-
initely. A recent report describes 10 patients with aHUS in whom
eculizumab was stopped; over a cumulative observation period
of 95 months, 3 patients relapsed within 6 weeks of discontinua-
tion but the drug was promptly restarted with complete recovery
(57). Patients with genetic forms of aHUS and unsuspected disease
activity may demonstrate clinical improvement after switching
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from plasma therapy to eculizumab treatment (58). Finally,
eculizumab enables successful kidney transplantation in those who
progress to ESKD (59).
POTENTIAL ROLE OF INFLAMMATION AS A THERAPEUTIC TARGET
Refocusing on the role of inflammation in HUS may prompt
a broader conception of the clinical problem and alternative
approaches to treatment. This aspect of glomerular injury has
not been a recent focus of research in HUS. However, we propose
that therapeutic agents can be developed to modify the inflamma-
tory mediators discussed in previous sections in order to attenuate
glomerular injury and prevent acute and chronic decline in kid-
ney function. This could include antagonists of chemokines such
as IL-8 and SDF or inhibition of cytokines that are elevated during
the course of HUS, such as TNF-α and IL-6. There are therapeutic
agents in clinical use and in varying stages of drug testing that
can interfere with the inflammatory response such as JAK/STAT
pathway and p38 inhibitors (60, 61). Furthermore, agents such as
exogenous angiopoietin-1 or the sphingosine-1-phosphate recep-
tor agonist FTY720 (fingolimod) may prevent the inflammatory
response to primary endothelial injury (25).
Targeting inflammatory mediators is emerging as a common
approach to treating a number of diseases. For example, mono-
clonal antibodies to TNF-α and IL-6 and inhibitors of p38 MAPK
used to treat patients with rheumatologic disorders are currently
being evaluated for treatment of glomerulonephritis. As TNF-α
has been proven to mediate glomerular and extra-renal injury
in STEC–HUS, these antibodies may also be beneficial in treat-
ing STEC–HUS (40–42). A recent review of the role of infection
and autoimmunity in glomerulonephritis points out the connec-
tion between HUS and various forms of glomerulonephritis and
supports our proposal that anti-inflammatory therapy may be
beneficial in HUS (62). It is important to note, however, that
based on published pre-clinical and clinical data (see above),
anti-inflammatory therapy may have a greater role in STEC–HUS
compared to aHUS (Table 2).
PROGNOSIS
Stx-PRODUCING STRAINS OF E. COLI -HEMOLYTIC UREMIC SYNDROME
The prognosis of STEC–HUS is generally good and most children
recover fully without subsequent relapses (63). The mortality rate
in children is <5% but higher in adults (64). Neurological events
are the most frequent cause of death (20). Short-term risk factors
for decreased renal function and poor outcomes (including death)
are the severity of the initial disease (e.g., oligo-anuria fever, leuko-
cytosis, and colitis) and the need for prolonged dialysis, i.e., more
than 7–14 days (65).
In patients who survive, renal abnormalities are the most com-
mon long-term complication. Children with persistent protein-
uria, i.e., urine protein:creatinine ratio>1, or hypertension 1 year
after resolution of the episode are at greater risk of progression to
CKD (66). In a meta-analysis of the long-term outcome of chil-
dren with STEC–HUS, up to 25% of children have evidence of
CKD including hypertension, proteinuria, or reduced GFR (67).
STEC–HUS accounts for 3–5% of patients with end stage kidney
disease in most registries. Children with STEC–HUS who require
kidney transplantation are not at risk for recurrent disease.
aHUS
The clinical outcome in children with non-familial aHUS is deter-
mined by the underlying disease (Table 1). In most cases, there
is recovery of renal function without any permanent loss of renal
function. The overall prognosis for patients with familial aHUS is
worse than STEC–HUS (Table 1). In patients with familial aHUS,
the mortality rate can reach 25% during the first episode and
children have a nearly ninefold higher mortality rate compared
to adults (11). Similar to STEC–HUS, in those who do not suc-
cumb to acute episodes of the disease, impaired renal function is
the most common long-term complication. Thus, up to 70–80%
of survivors progress to ESKD and require permanent dialysis.
A higher percentage of adults compared to children with aHUS
progress to ESKD after their first episode of disease (11).
The genotype of familial aHUS influences the clinical out-
comes. Patients with mutations in Factor H and Factor I have
a higher rate of progression to ESKD and a greater likelihood of
recurrent disease in a renal allograft. In contrast, mutations in
MCP are associated with a more favorable course and minimal
risk of recurrent disease post-kidney transplantation (11, 26).
CONCLUSION
Hemolytic uremic syndrome is a rare but important disease in
pediatric and adult patients. Although the clinical syndromes –
STEC–HUS and aHUS – overlap, there are significant differences
in the pathogenesis of these illnesses. The basis of treatment is
reversal of the abnormality triggering the episode of TMA cou-
pled with intensive supportive care. In some cases, improved
understanding of disease pathophysiology has resulted in marked
improvements in care, e.g., eculizumab in familial aHUS. How-
ever, the mortality and morbidity resulting from the TMA syn-
dromes continues to be substantial. It is anticipated that future
research in HUS will result in more sensitive diagnostic meth-
ods to detect disease earlier in the course of the illness. We
have attempted to expand the mechanism of disease in HUS
beyond direct vascular injury and complement-mediated dam-
age to include renal and systemic inflammation. It is hoped that
widening the scope in this way will facilitate the identification of
new disease pathways, prompt the design of therapeutic agents
that impact critical steps in the pathogenesis of each subtype of
HUS, and improve outcomes for patients with this rare but life
threatening illness.
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